[Ip-health] Achieving Innovation + Access in Global Pharmaceutical Markets

[Michael Palmedo]

This is a multi-part message in MIME format.
--
[ Picked text/plain from multipart/alternative ]

Achieving Innovation + Access in Global Pharmaceutical Markets

A Discussion with Professor John Barton
Stanford University School of Law

With Responses by
James Love, Knowledge Ecology International
Sean Flynn, American University Washington College of Law
Joseph Damond, Pfizer

Sponsored by
Knowledge Ecology International & American University Washington College
of Law Program on Information Justice and Intellectual Property

7pm on Thursday, February 19.
Washington College of Law, located at 4801 Massachusetts Ave., NW
Room TBA

Registration:
http://www.wcl.american.edu/secle/cle_form.cfm

Webcast:
www.wcl.american.edu/pijip/webcast.cfm

Professor John Barton, the former Chair of the UK Commission on
Intellectual Property Rights, and Pfizer CEO Jeff Kindler recently
outlined a proposed global framework on medicine pricing to protect
research and development incentives while promoting greater access to
drugs in low and middle income countries. The proposal calls for trade
agreement measures to restrain developed countries from excessive use of
price controls while promoting price discrimination in middle income
countries so that the richer segments of the population will pay more
than poorer segments. Meanwhile, many global access to medicines
campaigners and developing countries have been advocating for a new
research and development framework that would delink the price of the
product from the incentive to produce new medicines, e.g. through
various proposals for prize funds, direct government funding of research
and development and other means, while promoting full competition for
the supply of needed products.

PIJIP and KEI are pleased to announce that Professor Barton will
further explain and discuss his proposal at the Washington College of
Law on Thursday, February 19. Responders from civil society will comment
on the proposal and offer alternative models for the financing of
patent-driven research for health in middle and low income nations.